Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EPS (Weighted Average and Diluted) (2022 - 2025)

Bioregenx (BRGX) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.0 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 80.28% year-over-year to -$0.0; the TTM value through Sep 2025 reached -$0.02, down 287.57%, while the annual FY2024 figure was -$0.02, 100.0% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.0 in Q3 2025 per BRGX's latest filing, up from -$0.0 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.0 in Q2 2023 and bottomed at -$0.02 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.0, with a median of -$0.0 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 123015.02% in 2023, then skyrocketed 95.75% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.0 in 2022, then crashed by 961.24% to -$0.0 in 2023, then plummeted by 9084.39% to -$0.02 in 2024, then skyrocketed by 99.58% to -$0.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.0 in Q3 2025, -$0.0 in Q2 2025, and -$0.0 in Q1 2025.